ArticleThe World Allergy Organization journal2025
A preliminary investigation of the differences in immune responses in different strains of mice with localized allergic rhinitis tolerance models.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to compare systematically strain-specific immune differences between BALB/c and C57BL/6 mice in a local tolerance model and explore the underlying mechanisms. Methods: BALB/c and C57BL/6 mice received daily intranasal ovalbumin (OVA; 25 mg/ml, 10μl/nostril) or PBS for 15 weeks. Systemic responses (serum OVA-specific IgE, IgG1, IgG2a; splenocyte cytokine secretion: IL-4, IL-10, IFN-γ) and local nasal responses (symptoms, histopathology: polymorphonuclear/goblet cell infiltration; immunohistochemistry: TGF-β, IL-10, eotaxin; RNA-seq transcriptomics of nasal mucosa) were assessed at the 8th and 15th weeks. Results: BALB/c mice initially exhibited worsening nasal symptoms, which was followed by significant alleviation. In contrast, C57BL/6 mice showed a significant worsening of symptoms. Serum levels of IgE, IgG1, and IgG2a increased significantly over time in BALB/c mice. In C57BL/6 mice, serum IgE and IgG1 levels also increased significantly, while IgG2a levels showed no significant changes. In splenocyte supernatants, BALB/c mice showed IL-4 levels that initially increased significantly but later decreased significantly, whereas IL-10 levels were significantly elevated and sustained. Conversely, C57BL/6 mice exhibited no significant changes in these splenocyte cytokines. Within nasal mucosa, BALB/c mice displayed polymorphonuclear cell infiltration and significantly elevated eotaxin levels, which subsequently stabilized, alongside significant upregulation of TGF-β and IL-10 expression. At 15th week, C57BL/6 mice demonstrated significantly higher nasal PMN infiltration and eotaxin levels compared to BALB/c mice, but showed no significant increase in TGF-β or IL-10 compared to controls. RNA-seq analysis of nasal mucosa revealed that BALB/c mice at 15th week exhibited significant upregulation of genes involved in biological processes, tolerance-related signaling pathways, and negative regulatory pathways. Conversely, C57BL/6 mice showed significant upregulation of genes associated with cell synthesis- and secretion-related pathways. Conclusion: Based on the criteria defining "local tolerance" in this model-significant symptom attenuation despite allergen escalation coupled with downregulation of nasal inflammatory markers (eotaxin, polymorphonuclear cell infiltration)-local tolerance was successfully induced in BALB/c mice by long-term OVA stimulation, but not in C57BL/6 mice. The normal function of T regulatory cells is key to establishing local tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.